Provided by Tiger Trade Technology Pte. Ltd.

Vanda Pharmaceuticals

4.63
-0.1800-3.74%
Post-market: 4.58-0.0500-1.08%19:47 EDT
Volume:1.45M
Turnover:6.75M
Market Cap:279.94M
PE:-1.00
High:4.85
Open:4.85
Low:4.57
Close:4.81
52wk High:9.94
52wk Low:4.27
Shares:60.46M
Float Shares:47.66M
Volume Ratio:0.84
T/O Rate:3.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6291
EPS(LYR):-3.7413
ROE:-77.81%
ROA:-22.38%
PB:1.27
PE(LYR):-1.24

Loading ...

Vanda Pharmaceuticals director Duncan files initial beneficial ownership statement

Reuters
·
Apr 25

Vanda Pharmaceuticals announces annual shareholder meeting webcast

Reuters
·
Apr 24

Vanda Pharmaceuticals Adds Independent Director to Strengthen Board

TIPRANKS
·
Apr 23

Vanda Pharmaceuticals appoints Charles Duncan to board of directors

Reuters
·
Apr 23

Vanda Pharmaceuticals Appoints DR. Charles Duncan to Its Board of Directors

THOMSON REUTERS
·
Apr 23

Vanda files Form 3 for Senior VP, Medical Director Christos Polymeropoulos

Reuters
·
Apr 14

Vanda VP, Chief People Officer Scott Laverne Howell files initial beneficial ownership statement

Reuters
·
Apr 14

BUZZ-U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman

Reuters
·
Apr 10

Sector Update: Health Care Stocks Advance in Afternoon Trading

MT Newswires Live
·
Apr 10

Vanda urges FDA to drop proposal extending statutory drug review timelines

Reuters
·
Apr 09

Vanda Pharmaceuticals Inc - Proposal Would Eliminate FDA 180-Day Nda Review Requirement

THOMSON REUTERS
·
Apr 09

Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal From FY 2027 Legislative Agenda That Would Extend Drug Review Timelines

THOMSON REUTERS
·
Apr 09

Vanda Pharmaceuticals: Undervalued GLP-1 Adjunct Opportunity Driven by Tradipitant’s Pivotal Thetis Trial

TIPRANKS
·
Apr 09

Vanda starts Thetis trial of NEREUS to curb GLP-1 therapy vomiting

Reuters
·
Apr 09

Vanda Pharmaceuticals Announces Initiation of the Thetis Study, a Clinical Trial of Nereus™ for the Prevention of Vomiting Induced by Glp-1 Receptor Agonists

THOMSON REUTERS
·
Apr 09

Vanda Pharmaceuticals Inc - Topline Results From Thetis Study Expected by Q4 2026

THOMSON REUTERS
·
Apr 09

Vanda Pharmaceuticals Inc: Phase 2 Study Succeeded and Met Its Primary Endpoint

THOMSON REUTERS
·
Apr 09